WHAT IS CLAIMED IS:

1. A compound of formula **(I)**:



(I)

or a tautomer thereof, N-oxide thereof, stereoisomer thereof, or pharmaceutically acceptable salt thereof,

wherein

R^a, R^b, R^c and R^d are each independently selected from hydrogen, halogen, C_{1-3} alkyl or C_{1-3} haloalkyl;

X is CR^x or N;

Y is CR^y or N;

Z is CR^z or N;

R^x, R^y and R^z may be same or different and are independently selected from hydrogen, halogen or C_{1-3} alkyl;

G is selected from

 **(a),**  **(b),**  **(c),**  **(d)** or  **(e)**

wherein

R^e and R^f may be same or different and are independently selected from hydrogen, halogen, hydroxy, alkyl, haloalkyl, alkoxy, $-OR^g$, or both R^e and R^f directly bound to a common atom, may be joined to form an C_{3-6} cycloalkyl;

R^g is selected from hydrogen, substituted or unsubstituted C_{1-3} alkyl, or -(CO)R^h;

R^h is selected from hydrogen or alkyl and

R^1, R^2, R^3 and R^4 are each independently selected from hydrogen, halogen, haloalkyl and alkyl.

2. The Compound of claim 1, wherein the compound has formula **(I)**:



(I)

or a tautomer thereof, N-oxide thereof, stereoisomer thereof, or pharmaceutically acceptable salt thereof,

wherein

R^a, R^b, R^c and R^d are each independently selected from hydrogen, halogen or C_{1-3} alkyl;

X is CR^x or N;

Y is CR^y or N;

Z is CR^z or N;

R^x, R^y and R^z may be same or different and are independently selected from hydrogen, halogen or C_{1-3} alkyl;

G is selected from

 **(a1),**  **(b1),**  **(c1),**  **(d1),**  **(e1),**


(a2),

(b2),

(c2),

(d2) or

(e2)

wherein

R^e and R^f may be same or different and are independently selected from hydrogen, halogen, hydroxy, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy or $-O(CO)R^h$;

R^g is selected from hydrogen, substituted or unsubstituted C_{1-3} alkyl, or $-(CO)R^h$;

R^h is selected from hydrogen or alkyl; and

R^1, R^2, R^3 and R^4 are independently selected from hydrogen, halogen, C_{1-3} haloalkyl and C_{1-3} alkyl.

3. The Compound of claim 1, wherein the compound has formula **(IA) or (IB)**:


(IA)


(IB)

or a tautomer thereof, N-oxide thereof, stereoisomer thereof, or pharmaceutically acceptable salt thereof,

wherein R^a, R^b, R^c, R^d, X, Y, Z, R^e, R^f, R^1, R^2, R^3 and R^4 are as defined above in relation to the compound of formula (I).

4. The Compound of any one of claims 1-3, wherein

(i) any one or more of R^a, R^b, R^c and R^d are independently selected from hydrogen or halogen;

(ii) R^a, R^c and R^d are hydrogen and R^b is halogen; or

(iii) R^a, R^b and R^d are hydrogen and R^c is halogen.

5. The Compound of claim 4, wherein R^b is fluorine or chlorine.

6. The Compound of claim 4, wherein R^c is fluorine or chlorine.

7. The Compound of any one of claims 1-6, wherein X, Y and Z are independently selected from CH or N.

8. The Compound of claim 7, wherein

(i) Y and Z are CH and X is N;

(ii) X and Z are CH and Y is N; or

(iii) X and Y are CH and Z is N.

9. The Compound of any one of claims 1-8, wherein X and Y are CH and Z is CR^z.

10. The Compound of claim 9, wherein R^z is hydrogen or halogen.

11. The Compound of claim 10, wherein R^z is fluorine.

12. The Compound of any one of claims 1-11, wherein R^e and R^f are independently selected from hydrogen, hydroxy, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy and acetyloxy.

13. The Compound of claim 12, wherein R^e is hydroxy, C_{1-3} alkoxy or acetyloxy.

14. The Compound of claim 13, wherein R^e is hydroxy.

15. The Compound of claim 12, wherein R^f is C_{1-3} alkyl or C_{1-3} haloalkyl.

16. The Compound of claim 15, wherein R^f is methyl, ethyl or CF_3.

17. The Compound of claim 12, wherein R^e is hydroxy and R^f is C_{1-3} alkyl.

18. The Compound of claim 1, wherein

(i) R^e and R^f are hydrogen;

(ii) R^e and R^f are each independently selected from C_{1-3} alkyl; or

(iii) both R^e and R^f directly bound to a common atom, may be joined to form a C_{3-6} cycloalkyl.

19. The Compound of claim 18, wherein both R^e and R^f are hydrogen.

20. The Compound of claim 18, wherein both R^e and R^f are methyl.

21. The Compound of claim 1, wherein both R^e and R^f directly bound to a common atom, may be joined to form a cycloalkyl ring.

22. The Compound of any one of claims 1-21, wherein

(i) R^1, R^2, R^3 and R^4 are each independently selected from hydrogen or halogen;

(ii) R^1, R^2, R^3 and R^4 are each hydrogen;

(iii) R^1, R^2, R^3 and R^4 are each independently selected from halogen;

(iv) R^1, R^3 and R^4 are hydrogen and R^2 is halogen; or

(v) R^1, R^2 and R^4 are hydrogen and R^3 is halogen.

23. The Compound of claim 1, wherein

(i) any one or more of R^1, R^2, R^3 and R^4 is fluorine or chlorine;

(ii) R^1, R^3 and R^4 are hydrogen and R^2 is fluorine; or

(iii) R^1, R^2 and R^4 are hydrogen and R^3 is fluorine

24. The Compound of any one of claims 1-23, wherein G is selected from



25. The Compound of claim 24, wherein G is selected from



26. A compound selected from:

4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

(R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

(S)-(-)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

4-(4-Fluoro-3-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)benzyl)phthalazin-1(2H)-one;
4-((5-(3-Ethyl-3-hydroxy-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
7-Fluoro-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
(+)-7-Fluoro-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
(-)-7-Fluoro-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
6-Fluoro-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
7-Fluoro-4-((5-(5-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
(+)-7-Fluoro-4-((5-(5-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
(-)-7-Fluoro-4-((5-(5-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
4-((5-(5-Fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
(+)-4-((5-(5-Fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
(-)-4-((5-(5-Fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
7-Fluoro-4-((5-(6-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
7-Fluoro-4-((5-(6-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;
4-((2-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;
(-)-4-((2-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;
(+)-4-((2-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;
7-Fluoro-4-((2-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;

(-)-7-Fluoro-4-((2-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;

(+)-7-Fluoro-4-((2-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;

7-Fluoro-4-((2-(5-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-4-yl)methyl)phthalazin-1(2H)-one;

4-((5-(3-Hydroxy-2-oxo-3-(trifluoromethyl)indolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

(+)-4-((5-(3-Hydroxy-2-oxo-3-(trifluoromethyl)indolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

(-)-4-((5-(3-Hydroxy-2-oxo-3-(trifluoromethyl)indolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

4-(3-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)benzyl)phthalazin-1(2H)-one;

7-Fluoro-4-(4-fluoro-3-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)benzyl)phthalazin-1(2H)-one;

4-((5-(3-methoxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

4-(3-(3-Hydroxy-3-methyl-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-1-yl)benzyl)phthalazin-1(2H)-one;

3-Methyl-2-oxo-1-(5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)pyridin-3-yl)indolin-3-yl acetate;

4-(4-Fluoro-3-(2-oxoindolin-1-yl)benzyl)phthalazin-1(2H)-one;

4-(3-(3,3-Dimethyl-2-oxoindolin-1-yl)-4-fluorobenzyl)phthalazine-1(2H)-one;

4-((5-(3,3-Dimethyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

4-((5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one;

4-(3-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-4-fluorobenzyl)phthalazin-1(2H)-one; and

1'-(5-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)pyridin-3-yl)spiro[cyclopropane-1,3'-indolin]-2'-one;

or pharmaceutically acceptable salt thereof.

27. The compound of claim 1 selected from

4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one,

or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1 selected from

(R)-(+)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one,

or a pharmaceutically acceptable salt thereof.

29. The compound of claim 1 selected from

(S)-(-)-4-((5-(3-Hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one,

or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1 selected from

(+)-7-Fluoro-4-((5-(5-fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl) phthalazin-1(2H)-one,

or a pharmaceutically acceptable salt thereof.

31. The compound of claim 1 selected from

(+)-4-((5-(5-Fluoro-3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl) phthalazin-1(2H)-one,

or a pharmaceutically acceptable salt thereof.

32. A pharmaceutical composition comprising a compound of any one of claims 1-31 and a pharmaceutically acceptable carrier.

33. The pharmaceutical composition of claim 32, further comprising one or more additional therapeutic agents and mixtures thereof.

34. The pharmaceutical composition of claim 33, wherein the one or more additional therapeutic agents is an anti-cancer agent, an anti-inflammatory agent, an immunosuppressive agent, a steroid, a non-steroidal anti-inflammatory agent, an antihistamine, an analgesic, or a mixture thereof.

35. Use of the compound of any one of claims 1-31 in the manufacture of a medicament for the treatment of a PARP associated disease or disorder, wherein (a) an effective amount of the medicament is to be administered to a subject in need thereof, and (b) the PARP associated disease, disorder or condition is an immune system-related disease, a disease or disorder involving inflammation, cancer or other proliferative disease, a hepatic disease or disorder, or a renal disease or disorder.

36. The use of claim 35, wherein at least one other anti-cancer agent, anti-inflammatory agent, immunosuppressive agent, steroid, non-steroidal anti-inflammatory agent, antihistamine, analgesic, or any combination of any of the foregoing is to be administered simultaneously or sequentially to the subject.

37. The use of claim 35 or 36, wherein the PARP associated disease, disorder or condition is selected from inflammation, glomerulonephritis, uveitis, hepatic diseases or disorders, renal diseases or disorders, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation, graft rejection, graft-versus-host disease, lupus erythematosus, pulmonary fibrosis, dermatomyositis, thyroiditis, myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis, hepatitis, atopic dermatitis, asthma, Sjogren's syndrome, organ transplant rejection, multiple sclerosis, Guillain-Barre, autoimmune uveitis, autoimmune hemolytic anemia, pernicious anemia, autoimmune thrombocytopenia, temporal arteritis, anti-phospholipid syndrome, vasculitides, Wegener's granulomatosis, Behcet's disease, psoriasis, dermatitis herpetiformis, pemphigus vulgaris, vitiligo, Crohn's disease, colitis, ulcerative colitis, primary biliary cirrhosis, autoimmune

hepatitis, Type 1 or immune-mediated diabetes mellitus, Grave's disease. Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune disorder of the adrenal gland, systemic lupus erythematosus, polymyositis, dermatomyositis, ankylosing spondylitis, transplant rejection, skin graft rejection, arthritis, bone diseases associated with increased bone resorption, ileitis, Barrett's syndrome, adult respiratory distress syndrome, chronic obstructive airway disease; corneal dystrophy, trachoma, onchocerciasis, sympathetic ophthalmitis, endophthalmitis, gingivitis, periodontitis, tuberculosis, leprosy, uremic complications, nephrosis, sclerodermatitis, psoriasis, chronic demyelinating diseases of the nervous system, AIDS-related neurodegeneration, Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis viral or autoimmune encephalitis, autoimmune disorders, immune-complex vasculitis, systemic lupus and erythematodes, systemic lupus erythematosus (SLE), cardiomyopathy, ischemic heart disease hypercholesterolemia, atherosclerosis, preeclampsia, chronic liver failure, brain and spinal cord trauma, and cancer.

38. The use of claim 35 or 36, wherein the PARP associated disease, disorder or condition is selected from hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma, hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, promyelocytic leukemia, carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma, tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

39. The use of claim 35 or 36, wherein the PARP associated disease, disorder or condition is selected from carcinoma of the breast, ovarian cancer, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, pancreatic cancer or stomach cancer.

40. The use of claim 35 or 36, wherein the PARP associated disease, disorder or condition is selected from carcinoma of the breast or ovarian cancer.

41. The compound of any one of claims 1-31 for use in therapy.